CRDF

Cardiff Oncology is currently embroiled in a high-stakes legal conflict following a termination notice from its partner, Nerviano Medical Sciences. While the company maintains that the termination is ineffective and intends to proceed with its development plans, the disagreement centers on fundamental issues of patent inventorship and contractual obligations. The outcome of this dispute will determine whether Cardiff can move forward as the sole owner of its lead asset or if it will be hampered by litigation and potential loss of intellectual property rights. Investors are now weighing the possibility of a clean break against the risk of a catastrophic legal defeat.

The Q1 2026 filing presents a stark dichotomy between clinical promise and financial peril. On one hand, the FDA's alignment on the Phase 3 trial design for onvansertib provides a concrete catalyst and validates the drug's potential as a breakthrough in mCRC. On the other hand, the explicit 'going concern' qualification and the legal battle with Nerviano introduce systemic risks that could derail the entire project regardless of clinical success. Investors are now faced with a high-stakes trade-off: the ability to capture the upside of a potential oncology blockbuster versus the risk of total loss due to insolvency or license termination. The immediate focus shifts to the upcoming ASCO presentation and any updates regarding the Nerviano dispute, as these will determine if the company can secure the funding necessary to execute its Phase 3 roadmap without destroying existing shareholder value.